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tively. For hypertensive patients treated with statins (8 included trials) the stan-
dardized effect size of DSBP andDDBPwas 0.07 (95%CI: -0.07-0.21; p0.33) and -0.12
(95%CI: -0.36-0.11; p0.31), respectively. CONCLUSIONS: Despite previous sugges-
tions, statin therapy in normotensive or hypertensive patients does not lead to
reductions in systolic and diastolic blood pressure. Despite these results, however,
the routine use of statins, especially in patients with hypertension should be al-
ways considered due to the essential reduction of cardiovascular events.
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OBJECTIVES: The first coronary drug-eluting stent gained its market approval in
Europe 2002. Many different drug-eluting stents came to the market worldwide
since then. In Taiwan, National Health Insurance has partially reimbursed drug-
eluting stents since 2006. The number of claimed usage increased from 521 (year
2006) up to 14,311 (year 2010), and total claimed reimburse went up from NTD 15
million to 300 million. The impact to the NHI has been increasing. The aim of this
study is to summarize the results of Taiwan drug-eluting stents studies for future
researches.METHODS:We systematically searched three bibliographic databases:
EMBASE, PubMed and Taiwan National Central Library for studies utilizing Taiwan
local data. In order to collect as many local studies as we can, no restrictions were
applied onpublication year, study type, disease, patients, intervention, comparator
and outcomes. RESULTS: Among the 73 studies we identified in EMBASE and
PubMed, only one randomized control trial was found. The authors tried to evalu-
ate the preventive outcome of phosphorycholine-coated dexamethasone stent by
observing restenosis rate. We then expanded our analysis scopes to controlled
trials, and additional 26 studieswere identified and 3 studiesmatched our research
question. Their topics were about “1 year follow-up after PCI with Titan versus
TAXUS stents”, “gender differences in patients undergoing coronary stenting” and
“the effects of starting statin therapy before PCI with drug-eluting stents”. On the
other part of our research at Taiwan National Central Library, there was no paper
matched our including criteria. Most of the papers included there were coronary
stents design related articles. CONCLUSIONS: Based on systematically research
results, we only found one randomized control trial fully used Taiwan local data.
Lack of comparative effectiveness on local stents usage could pose a problemwhen
considering evidence-based decision making.
PCV7
IMPLEMENTING AND EVALUATING PHARMACIST-MANAGED WARFARIN
SERVICE IN INPATIENT AND OUTPATIENT SETTING IN TAIWAN
Wang YP1, Tseng JH2, Huang SY3
1Taipei Medical University – Shuang Ho Hospital, New Taipei City, New Taipei City, Taiwan,
2Taipei Medical University – Shuang Ho Hospital, New Taipei City, New Taipei City, Taiwan,
3Taipei Medical University – Shuang Ho Hospital, New Taipei City, New Taipei city, Taiwan
OBJECTIVES: To identify approaches and to evaluate efficacy of implementing an
warfarin service program involving pharmacists. METHODS: The pharmacy de-
partment worked with the medical staff to establish a warfarin service, including
guidelines approval. Pharmacist-managed warfarin service was provided in neu-
rology ward or for patients who were referred from physicians, and others re-
mained standard care of anticoagulants. Data was collected for 3 months after the
service implementation (March toMay, 2011). Demographic and clinical character-
istics as well as laboratory and clinical data were retrieved from institutional elec-
tronic databases and compared between the pharmacist-managed and standard-
care cohort. Comparisons between study groups were conducted using a 2 or
Fisher’s Exact test for categorical variables and a two sample t-test or Wilcoxon
rank sum test for continuous variables. RESULTS: INR below the therapeutic range
were observed less frequently (53.3% vs. 61.1%, P0.35) and better control for INR
within rangewere reportedmore (28.6% vs. 26.9%, P0.80) in pharmacist-managed
arm, when compared to standard-care arm. There were also fewer number of
patients never reaching the INR goal during the whole study period (35.7% vs.
46.1%, P0.52). None of major bleeding event occurred, however, one thrombotic
event was observed in each arm. By intervention of pharmacists, possible adverse
event and medication errors were also blocked. For example, one patient dis-
charged while INR over 5 without any physicians’ or nurses’ awareness was ac-
tively informed by pharmacist, then contacted to be cautious with possible bleed-
ing risks andmanagement. CONCLUSIONS: Pharmacist-managed warfarin service
had a positive impact on anticoagulationmanagement. This study provides further
evidence to support the of role pharmacists in anticoagulant therapy. We plan to
expend the warfarin service experience to the overall institution in the future.
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OBJECTIVES: To develop evaluation criteria comparing efficacy and safety of anti-
hypertensive drugs and to perform comparative analysis based on the developed
criteria on the pre- existing antihypertensive drugs on reimbursement list in Korea.
METHODS: A total of 1226 items with 131 ingredients were categorized into 5
classes: Diuretics, -blocker, Calcium channel blocker, Angiotensin—converting-
enzyme inhibitors, Angiotensin-Receptor-blocker. Proxy and final outcomes eval-
uating efficacy of antihypertensive drugswere determined based on previous stud-
ies and opinion of experts. For proxy outcomes, Systolic Blood Pressure and
Diastolic Blood Pressure were used while all-cause mortality, cardiovascular mor-
tality, and cardiovascular morbidity were used as final outcomes. Proper criteria
evaluating safety are impossible to choose because symptoms and frequency of
adverse event varies depending on classes. Systematic review literatures in Korea
and other countries were searched using databases such as Pubmed, Cochrane,
Embase, Center for Review&Dissemination, KMBase, and KoreaMed. In addition, 6
assessment reports from overseas health technology institutions and opinions of
clinical experts were referenced. Finally, 7 literatures using proxy outcomes and 8
literatures using final outcomes were reviewed in-depth after through screening.
Additional statistical analysis was not performed. RESULTS: On in-depth exami-
nation, there was no profound evidence depicting difference in proxy and final
outcomes among classes and among ingredients in the same class. Results of 6
overseas technical reports aforementioned were the same as the ones of SR liter-
atures. Opinions of clinical experts confirmed the findings of in-depth examination
in proxy outcomes adding that efficacy in final outcomes can be different depend-
ing on the co-morbidity status. CONCLUSIONS: It was not proven that a particular
class or ingredient is superior to others. Therefore, it is expected that if reimburse-
ment list is reorganized based on this result, improvement of public health and
saving of health insurance finance is feasible without depriving the prescription
rights of clinicians.
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OBJECTIVES: Stevioside is a major constituent of the plant Stevia rebaudiana Ber-
toni (SRB). Its beneficial effect on human blood pressure has been demonstrated in
many studies, with no significant adverse effects being reported. This meta-anal-
ysis was aimed to evaluate the efficacy and safety of stevioside against placebo in
blood pressure control in hypertensive patients. METHODS: A systematic search
for relevant studieswas performed of the PubMed, ScienceDirect, Cochrane Library
and Wiley Online Library databases from their respective inception until Fabruary
2012. The bibliography of the retrieved studies was also examined. Stevia rebaudi-
ana Bertoni, stevioside, hypertension and randomized controlled trial were used as
searching keywords. The studies were included if they: 1. were randomized con-
trolled trials (RCTs) comparing stevioside from SRB with placebo in hypertensive
patients; 2. reported on systolic blood pressure (SBP) and diastolic blood pressure
(DBP); and 3. were published in English. Data were pooled using the inverse vari-
ance-weighted method and statistical analyses were performed using the Review
Manager (RevMan) version 5.1.4. RESULTS: Three RCTs involving altogether 280 pa-
tients were included in the analysis. Stevioside was found to be effective in reducing
SBP, with no significant effect on DBP, compared to placebo. The pooled mean differ-
ences in SBP and DBP were -10.43 mmHg (95% CI: -12.15 to -8.72 mmHg, p0.01) and
-6.67mmHg (95%CI: -13.23 to -0.10mmHg, p0.05), respectively. No significant differ-
ence in adverse events was reported between the two groups (OR: 1.32, 95% CI: 0.61 to
2.86). CONCLUSIONS: Our findings suggest the efficacy of stevioside in reducing
SBP but not DBP in hypertensive patients. Additionally, stevioside was shown to
produce no significant adverse events in this group of patients.
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OBJECTIVES: Cardiovascular diseases are the most frequent cause of morbidity
andmortality inmany countries. That explains whymedications for the treatment
of cardiovascular diseases are group of drugs with largest consumption, and ACE
inhibitors take a large part in the consumption. The aim of this study was to
analyze the consumption of prescribed ACE inhibitors, in Serbia during year 2009.
METHODS: The data about the use of ACE inhibitors were obtained from the Re-
public Fund of Health Insurance of the Serbia (RFZO). RESULTS: Total consumption
of ACE inhibitors in year 2009 was 176,29 DDD and total financial outlay was
59.772.897,11€. Largest use of plain ACE inhibitors was for enalapril (78,32 DDD),
fosinopril (20,09 DDD), ramipril (19,11 DDD) and cilazapril (14,19 DDD). The volume
of their consumption is not in accordance with the funding spent for these prod-
ucts. Enalapril, which has the highest percentage of consumption in this group of
44,43%, has 28,73% of total allocated funds, while the consumption for fosinopril
amounts to 11,40%while 18,69%of fundswithin the group is allocated for this drug. In
Norway and Sweden, country with developed pharmacotherapeutic practice, highest
usage of plain ACE inhibitors was for ramipril and enalapril. In these countries, other
more expensive products are significantly less likely to be used. If the consumption
structure of ACE inhibitors in Serbia in 2009 was as in Norway, but with the same
volume of consumption RFZO would save about 9.500.000,00€ only for plain ACE
inhibitors.CONCLUSIONS:Viewed from the perspective of the RFZO, large financial
resources would be saved if the structure of the utilized ACE inhibitors in Serbia
was more similar to the country with developed pharmacotherapeutic practice.
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